Literature DB >> 19404979

DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.

Olivier Toutirais1, Florian Cabillic, Gaëlle Le Friec, Samuel Salot, Pascal Loyer, Matthieu Le Gallo, Mireille Desille, Cécile Thomas de La Pintière, Pascale Daniel, Françoise Bouet, Véronique Catros.   

Abstract

Human Vgamma9Vdelta2 T lymphocytes can be activated by nonpeptidic antigens such as the mevalonate pathway-derived isopentenyl pyrophosphate or synthetic phosphoantigen such as bromohydrin pyrophosphate. They display a strong cytotoxic activity against several tumor types, including hepatocellular carcinoma (HCC). Little is known about the mechanisms underlying Vgamma9Vdelta2 T-cell recognition of tumor cells, but there is strong evidence that activating NK receptors play a role in gammadelta T-cell cytotoxicity. In this study, we showed that the two NK receptors DNAX accessory molecule-1 (DNAM-1) and CD96 were expressed by Vgamma9Vdelta2 T cells. The ligands Nectin-like-5 specific of both DNAM-1 and CD96, and also Nectin-2, an additional ligand of DNAM-1, were present on all HCC cell lines analyzed. Furthermore, we demonstrated by mAb-mediated masking experiments that cytotoxicity against HCC cells as well as IFN-gamma production in gammadelta T cells were dependent on DNAM-1. Our experiments indicated that Nectin-like-5 but not Nectin-2 was involved in DNAM-1-dependent gammadelta T-cell functions. We did not reveal a role for CD96 in the killing of HCC cells. Finally, we showed by combined mAb-mediated blockade that DNAM-1 and NKG2D could cooperate in the cell lysis of HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19404979     DOI: 10.1002/eji.200838409

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  42 in total

1.  Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells.

Authors:  Sebastian Seth; Quan Qiu; Simon Danisch; Michael K Maier; Asolina Braun; Inga Ravens; Niklas Czeloth; Rebecca Hyde; Oliver Dittrich-Breiholz; Reinhold Förster; Günter Bernhardt
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

Review 2.  Role of gamma-delta T-cells in cancer: another opening door to immunotherapy.

Authors:  Diego Marquez-Medina; Joel Salla-Fortuny; Antonieta Salud-Salvia
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

Review 3.  γδ T cells in liver diseases.

Authors:  Xuefu Wang; Zhigang Tian
Journal:  Front Med       Date:  2018-02-14       Impact factor: 4.592

Review 4.  The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?

Authors:  Domenico Galati; Serena Zanotta; Marialuisa Bocchino; Rosaria De Filippi; Antonio Pinto
Journal:  Cancer Immunol Immunother       Date:  2021-01-01       Impact factor: 6.968

Review 5.  γδ T cell receptor ligands and modes of antigen recognition.

Authors:  Eric Champagne
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2011-02-06       Impact factor: 4.291

6.  Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.

Authors:  Swati Dhar; Shubhada V Chiplunkar
Journal:  Cancer Immun       Date:  2010-11-12

7.  γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes.

Authors:  Irma Airoldi; Alice Bertaina; Ignazia Prigione; Alessia Zorzoli; Daria Pagliara; Claudia Cocco; Raffaella Meazza; Fabrizio Loiacono; Barbarella Lucarelli; Maria Ester Bernardo; Giulia Barbarito; Daniela Pende; Alessandro Moretta; Vito Pistoia; Lorenzo Moretta; Franco Locatelli
Journal:  Blood       Date:  2015-01-22       Impact factor: 22.113

8.  Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.

Authors:  Atif S M Idrees; Tomoharu Sugie; Chiyomi Inoue; Kaoru Murata-Hirai; Haruki Okamura; Craig T Morita; Nagahiro Minato; Masakazu Toi; Yoshimasa Tanaka
Journal:  Cancer Sci       Date:  2013-03-19       Impact factor: 6.716

9.  Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma.

Authors:  Tsutomu Nakazawa; Mitsutoshi Nakamura; Young Soo Park; Yasushi Motoyama; Yasuo Hironaka; Fumihiko Nishimura; Ichiro Nakagawa; Shuichi Yamada; Ryosuke Matsuda; Kentaro Tamura; Tadashi Sugimoto; Yasuhiro Takeshima; Akiko Marutani; Takahiro Tsujimura; Noriko Ouji; Yukiteru Ouji; Masahide Yoshikawa; Hiroyuki Nakase
Journal:  J Neurooncol       Date:  2013-09-24       Impact factor: 4.130

10.  Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression.

Authors:  Alissa Visram; Surendra Dasari; Emilie Anderson; Shaji Kumar; Taxiarchis V Kourelis
Journal:  Blood Cancer J       Date:  2021-03-01       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.